These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9798482)

  • 1. [What pharmacodynamic elements affect Augmentin in man?].
    Jehl F
    Presse Med; 1998 Sep; 27 Suppl 4():20-1. PubMed ID: 9798482
    [No Abstract]   [Full Text] [Related]  

  • 2. [Choice of antibiotics in lower respiratory infections: what does pharmacodynamics bring? Clinical application of pharmacodynamic data].
    Goldstein F
    Presse Med; 1998 Sep; 27 Suppl 4():22-3. PubMed ID: 9798483
    [No Abstract]   [Full Text] [Related]  

  • 3. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
    Lode H
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
    [No Abstract]   [Full Text] [Related]  

  • 4. Amoxicillin-clavulanic acid: additions and corrections.
    Ackerman BH; Wynne B
    Mayo Clin Proc; 1999 Oct; 74(10):1050-1. PubMed ID: 10918874
    [No Abstract]   [Full Text] [Related]  

  • 5. The in-vitro activities of co-amoxiclav and other oral antibiotics against Streptococcus pneumoniae isolates exhibiting intermediate susceptibility to penicillin.
    Washington JA; Felmingham D
    J Antimicrob Chemother; 1998 Sep; 42(3):405-6. PubMed ID: 9786488
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibilities to the compounds.
    Gracia M; Ponte C; Soriano F
    Int J Antimicrob Agents; 2005 Apr; 25(4):352-3. PubMed ID: 15784320
    [No Abstract]   [Full Text] [Related]  

  • 7. [Predictive pharmacodynamic criteria and efficacy of augmentin 1 g/125 mg in 2 doses per day].
    Jehl F
    Presse Med; 2000 Sep; 29(26 Suppl):9-10. PubMed ID: 11045112
    [No Abstract]   [Full Text] [Related]  

  • 8. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM; Prause JL; Danziger LH; Pendland SL
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elements of design: the knowledge on which we build.
    MacGowan AP
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():6-11. PubMed ID: 14759228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML; García Y; Valero E; Amores R; Fuentes F
    Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of co-amoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation.
    Prieto J; Giménez MJ; Balcabao IP; Gómez-Lus ML; Aguilar L
    J Chemother; 1999 Oct; 11(5):345-8. PubMed ID: 10632379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of the bactericide activity of the combination amoxycillin/clavulanic acid and its possible effects in the resistance of beta-lactam drugs].
    Prieto J; Frías J; Alou L; Carcas A
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():12-5. PubMed ID: 9717154
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R; Alou L; Giménez MJ; Sevillano D; Gómez-Lus ML; Aguilar L; Prieto J
    Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The postantibiotic effect of amoxicillin/clavulanic acid on Streptococcus pneumoniae strains of different serotypes and penicillin sensitivity].
    García Y; Gómez MJ; Ramos MC; Gómez-Lus ML; Prieto J
    Rev Esp Quimioter; 1998 Jun; 11(2):157-60. PubMed ID: 9795302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens.
    Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
    Int J Antimicrob Agents; 2007 Jan; 29(1):39-43. PubMed ID: 17189093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
    Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
    Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the pneumologist].
    Poirier R
    Presse Med; 1998 Sep; 27 Suppl 4():14-5. PubMed ID: 9798478
    [No Abstract]   [Full Text] [Related]  

  • 19. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin.
    Koeth LM; Good CE; Saunders KA; Jakielaszek C
    Int J Antimicrob Agents; 2004 Aug; 24(2):144-9. PubMed ID: 15288313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.